First cell-reprogramming drug enters trials

NeoLimit has developed a new biotechnology technology focused on reprogramming liver cells to combat aging, successfully discovering an initial drug that turns back the clock in aged liver cells. The company announced it has raised $435 million in funding to begin human clinical trials next year to test the effectiveness of this treatment in restoring youthful liver, immune, and vascular functions. This AI-powered technique aims to reset cellular software without altering DNA, representing an effort within the biotech industry to reverse the effects of aging and improve health in the elderly.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل